Haleon (HLN) Capital Expenditures (2021 - 2023)
Haleon (HLN) posted Capital Expenditures of -$151.4 million for Q4 2023, down 65.51% on a QoQ basis from -$91.5 million in Q4 2022, and down 65.51% year-over-year from -$439.0 million in Q4 2022.
Haleon (HLN) Capital Expenditures (2021 - 2023) Analysis & Trends
Haleon's Capital Expenditures history runs 3 years deep, the most recent figure standing at -$151.4 million for Q4 2023.
- Quarterly Capital Expenditures fell 65.51% year-over-year to -$151.4 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was -$458.9 million (changed N/A YoY) and the FY2025 annual result came in at $424.6 million, up 32.85% from the prior year.
- Capital Expenditures was -$151.4 million for Q4 2023 at Haleon, down from -$91.5 million in the prior quarter.
- Across five years, Capital Expenditures topped out at -$91.5 million in Q4 2022 and bottomed at -$151.4 million in Q4 2023.
- A 3-year average of -$114.7 million and a median of -$108.0 million in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2022 — Capital Expenditures climbed 23.74% — and 2023, when it tumbled 65.51%.
- Haleon's Capital Expenditures stood at -$120.0 million in 2021, then increased by 23.74% to -$91.5 million in 2022, then tumbled by 65.51% to -$151.4 million in 2023.
- Business Quant data shows HLN's Capital Expenditures at -$151.4 million in Q4 2023, -$91.5 million in Q4 2022, and -$96.0 million in Q3 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 168.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 110.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 1.95 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 99.60 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 39.90 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.40 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 51.00 Mn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 10.80 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -151.42 Mn |
| Dec 31, 2023 | -151.42 Mn |
| Dec 31, 2022 | -91.49 Mn |
| Dec 31, 2022 | -91.49 Mn |
| Sep 20, 2022 | -96.04 Mn |
| Sep 20, 2022 | -96.04 Mn |
| Dec 31, 2021 | -119.97 Mn |
| Dec 31, 2021 | -119.97 Mn |